MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock (14, 228...
$429M
Proceeds from debt
issuances, net
$49M
Proceeds from issuance of
common stock pursuant...
$10M
Proceeds from maturities
of marketable...
$1,073M
Proceeds from sales of
marketable securities
$71M
Net cash provided by
financing activities
$488M
Net cash provided by
(used in) investing...
$66M
Canceled cashflow
$1,078M
Net increase
(decrease) in cash, cash...
$72M
Canceled cashflow
$482M
Stock-based compensation
expense
$60M
Accounts payable (24, ,
and to a related...
$24M
Depreciation and
amortization
$10M
Receivable from
collaboration partners (6, 14...
-$9M
Other liabilities
$8M
Noncash lease expense
$7M
Other assets (, 6 and
(4) from a related...
-$5M
Other items, net
$1M
Purchases of marketable
securities
$1,076M
Purchases of property and
equipment
$2M
Net cash used in
operating activities
-$482M
Canceled cashflow
$124M
Total revenues
$247M
Partnership reimbursements
-$127M
Interest income, net
-$33M
Net loss
-$353M
Deferred revenue ((240),
(56) and (77) to a...
-$240M
Canceled cashflow
$407M
Amortization of discounts on
marketable securities
$13M
Late-stage development
programs
$274M
Compensation and personnel
costs
$245M
Early-stage development and
preclinical programs
$141M
Other segment items
$90M
Depreciation and
amortization
$10M
Back
Back
Cash Flow
source: myfinsight.com
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)